S&P 500 Futures
(1.10%) 5 147.50 points
Dow Jones Futures
(1.26%) 38 864 points
Nasdaq Futures
(1.54%) 17 922 points
Oil
(0.15%) $79.07
Gas
(1.13%) $2.06
Gold
(0.17%) $2 313.60
Silver
(0.06%) $26.85
Platinum
(1.22%) $974.30
USD/EUR
(-0.53%) $0.927
USD/NOK
(-1.22%) $10.86
USD/GBP
(-0.44%) $0.794
USD/RUB
(0.49%) $91.57

Aktualne aktualizacje dla Alpine Immune Sciences [ALPN]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
BUY
80.00%
return 58.35%
SELL
46.67%
return -32.30%
Ostatnio aktualizowano2 geg. 2024 @ 23:00

0.00% $ 64.60

KUPNO 1213 min ago

@ $64.59

Wydano: 2 geg. 2024 @ 19:55


Zwrot: 0.02%


Poprzedni sygnał: geg. 2 - 17:48


Poprzedni sygnał: Sprzedaż


Zwrot: -0.08 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.41% compare to its pairs and should correct upwards.

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases...

Stats
Dzisiejszy wolumen 2.81M
Średni wolumen 2.26M
Kapitalizacja rynkowa 4.24B
EPS $0 ( 2024-03-18 )
Następna data zysków ( $-0.410 ) 2024-06-12
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -100.94
ATR14 $0.0900 (0.14%)
Insider Trading
Date Person Action Amount type
2024-04-25 Topper James N Buy 1 200 000 Common Stock
2024-04-25 Topper James N Sell 19 Common Stock
2024-04-25 Topper James N Sell 1 200 000 Warrant (Right to Buy)
2024-04-03 Fuhs Ulrich Martin Sell 0 Common Stock
2024-04-03 Fuhs Ulrich Martin Sell 75 000 Stock Option (Right to buy)
INSIDER POWER
-20.04
Last 100 transactions
Buy: 5 391 092 | Sell: 8 249 832
Korelacja (AI algo v.1.1b): Undervalued: 0.41% $64.85 paired level. (Algorytm śledzi zmiany najbardziej skorelowanych akcji w czasie rzeczywistym i natychmiast aktualizuje)

Wolumen Korelacja

Długi: -0.18 (neutral)
Krótki: -0.59 (weak negative)
Signal:(48) Neutral

Alpine Immune Sciences Korelacja

10 Najbardziej pozytywne korelacje
NKTR0.962
BOCN0.954
IXAQ0.954
BCSA0.952
FCNCA0.951
IZEA0.95
SZZL0.949
SVFAU0.946
MSDA0.946
NSYS0.946
10 Najbardziej negatywne korelacje
AKTX-0.963
ALLR-0.959
APPH-0.951
HCDI-0.951
CASA-0.949
SILK-0.944
JACK-0.943
SHEN-0.943
HAIN-0.94
PERI-0.939

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alpine Immune Sciences Korelacja - Waluta/Towar

The country flag 0.07
( neutral )
The country flag 0.08
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.08
( neutral )

Alpine Immune Sciences Finanse

Annual 2023
Przychody: $58.88M
Zysk brutto: $58.30M (99.02 %)
EPS: $-0.640
FY 2023
Przychody: $58.88M
Zysk brutto: $58.30M (99.02 %)
EPS: $-0.640
FY 2022
Przychody: $30.06M
Zysk brutto: $29.47M (98.01 %)
EPS: $-1.730
FY 2021
Przychody: $23.44M
Zysk brutto: $0.00 (0.00 %)
EPS: $-1.980

Financial Reports:

No articles found.

Alpine Immune Sciences

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej